Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study

被引:19
作者
Hattori, Arihiro [1 ]
Kawamura, Itta [1 ]
Yamada, Yoshihisa [1 ]
Kanamori, Hiromitsu [1 ]
Aoyama, Takuma [1 ]
Ushikoshi, Hiroaki [1 ]
Kawasaki, Masanori [1 ]
Nishigaki, Kazuhiko [1 ]
Tamemura, Genzou [1 ]
Minatoguchi, Shinya [1 ]
机构
[1] Gifu Univ, Grad Sch Med, Dept Cardiol, Gifu, Japan
来源
BMJ OPEN | 2013年 / 3卷 / 09期
关键词
GLUCAGON-LIKE PEPTIDE-1; ISCHEMIA-REPERFUSION INJURY; BRAIN NATRIURETIC PEPTIDE; DIASTOLIC FUNCTION; HEART; AMIDE; DOGS;
D O I
10.1136/bmjopen-2013-003201
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: We aimed to elucidate usefulness of plasma glucagon-like peptide-1 (GLP-1) levels for the assessment of left ventricular (LV) dysfunction by examining the relationship among plasma GLP-1 levels, expression of cardiac GLP-1 receptors and LV function in patients with impaired and preserved LV function. Design: Prospective study. Setting: Number of participating center: 1, Gifu, Japan. Participants: Number of patients enrolled: 102 patients who underwent elective cardiac catheterisation for coronary artery disease, cardiomyopathy and valvular heart disease, and 6 patients who underwent cardiac biopsy. Results: The plasma GLP-1 level was significantly increased in patients with impaired LV function (5.7 +/- 1.9 pmol/L) as compared with those with preserved LV function (2.7 +/- 1.6 pmol/L). Plasma GLP-1 and plasma brain natriuretic peptide (BNP) levels were inversely correlated with the LV ejection fraction(EF), respectively. Plasma GLP-1 level positively correlated with plasma BNP level. Multivariate logistic regression analysis revealed that plasma GLP-1 level was an independent determinant of the impaired LV function, whereas plasma BNP level was not. Intensity of immunostaining for GLP-1 receptor protein was significantly enhanced in patients with impaired LV function compared with those with preserved LV function. Conclusions: The plasma GLP-1 level was increased in patients with impaired systolic LV function and inversely correlated with the LVEF. The expressions of GLP-1 receptors were enhanced in hearts with impaired LV function. These may suggest that endogenous GLP-1-GLP-1 receptor system serves as a compensatory mechanism for systolic LV dysfunction.
引用
收藏
页数:9
相关论文
共 25 条
  • [1] Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    Ban, Kiwon
    Noyan-Ashraf, M. Hossein
    Hoefer, Judith
    Bolz, Steffen-Sebastian
    Drucker, Daniel J.
    Husain, Mansoor
    [J]. CIRCULATION, 2008, 117 (18) : 2340 - 2350
  • [2] Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake via p38α MAP Kinase-Mediated, Nitric Oxide-Dependent Mechanisms in Conscious Dogs With Dilated Cardiomyopathy
    Bhashyam, Siva
    Fields, Anjali V.
    Patterson, Brandy
    Testani, Jeffrey M.
    Chen, Li
    Shen, You-tang
    Shannon, Richard P.
    [J]. CIRCULATION-HEART FAILURE, 2010, 3 (04) : 512 - 521
  • [3] Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    Bose, AK
    Mocanu, MM
    Carr, RD
    Brand, CL
    Yellon, DM
    [J]. DIABETES, 2005, 54 (01) : 146 - 151
  • [4] Circulation and degradation of GIP and GLP-1
    Deacon, CF
    [J]. HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 761 - 765
  • [5] The biology of incretin hormones
    Drucker, DJ
    [J]. CELL METABOLISM, 2006, 3 (03) : 153 - 165
  • [6] Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
    Grieve, David J.
    Cassidy, Roslyn S.
    Green, Brian D.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (08) : 1340 - 1351
  • [7] Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits
    Iwasa, Masamitsu
    Yamada, Yoshihisa
    Kobayashi, Hiroyuki
    Yasuda, Shinji
    Kawamura, Itta
    Sumi, Shohei
    Shiraki, Takeru
    Yamaki, Takahiko
    Ushikoshi, Hiroaki
    Hattori, Arihiro
    Aoyama, Takuma
    Nishigaki, Kazuhiko
    Takemura, Genzou
    Fujiwara, Hisayoshi
    Minatoguchi, Shinya
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (01) : 119 - 131
  • [8] Antidiabetic Drug Voglibose Is Protective Against Ischemia-Reperfusion Injury Through Glucagon-Like Peptide 1 Receptors and the Phosphoinositide 3-Kinase-Akt-Endothelial Nitric Oxide Synthase Pathway in Rabbits
    Iwasa, Masamitsu
    Kobayashi, Hiroyuki
    Yasuda, Shinji
    Kawamura, Itta
    SumiMd, Shohei
    Yamada, Yoshihisa
    Shiraki, Takeru
    Yamaki, Takahiko
    Ushikoshi, Hiroaki
    Aoyama, Takuma
    Nishigaki, Kazuhiko
    Takemura, Genzou
    Fujiwara, Takako
    Fujiwara, Hisayoshi
    Minatoguchi, Shinya
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 55 (06) : 625 - 634
  • [9] GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
    Kim, Minsuk
    Platt, Mathew J.
    Shibasaki, Tadao
    Quaggin, Susan E.
    Backx, Peter H.
    Seino, Susumu
    Simpson, Jeremy A.
    Drucker, Daniel J.
    [J]. NATURE MEDICINE, 2013, 19 (05) : 567 - 575
  • [10] Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
    Knudsen, LB
    Pridal, L
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 318 (2-3) : 429 - 435